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The metabolism of arachidonic acid by both cyclooxygenase and lipoxygenase 
pathways  produces  several  potent  mediators  of  immune-induced  and  other 
inflammatory reactions (1-5). Inhibition of the cyclooxygenase pathway appears 
to  account  for  the  major  effects of the  nonsteroidal  antiinflammatory  drugs 
(NSAID). 1 However, inhibition  of one pathway of arachidonic acid metabolism 
may alter the rates of formation and quantities  of products of other pathways, 
and therefore, some of the effects of the NSAID might be secondary to changes 
in the formation of lipoxygenase products. 
Acute systemic anaphylaxis and other immediate hypersensitivity reactions are 
accompanied by the release of several mediators,  including  histamine,  platelet 
activating  factor,  prostaglandins,  thromboxane,  and  leukotrienes  (3-6).  Slow 
reacting  substance  of anaphylaxis  (SRS-A)  is  now  known  to  consist  of three 
sulfidopeptide leukotrienes  (SPLT),  LTC4 (leukotriene  C4),  LTD4, and  LTE4, 
which  are  produced  following  the  action  of the  enzyme  5-1ipoxygenase  on 
arachidonic acid. These SPLTs have several properties which suggest that they 
may participate in allergic reactions, including bronchoconstriction and alteration 
in vascular permeability. The other major product of the 5-1ipoxygenase pathway, 
LTB4, has potent effects on chemotaxis, adherence, and other actions of leuko- 
cytes (3-5). 
We examined  the production  of several eicosanoids formed during  systemic 
anaphylaxis in anesthetized sheep, in vivo. Our results show that cyciooxygenase 
blockade by indomethacin is associated with a marked increase in the concentra- 
tion of LTE4 in lung lymph. These studies suggest that some of the pharmacologic 
effects of NSAID  may  be  related  to  increased  elaboration  of 5-1ipoxygenase 
products, in addition to cyclooxygenase blockade. 
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of Health, Bethesda, MD. 
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Materials and Methods 
Sheep Anaphylaxis.  Suffolk sheep weighing ~30 kg were immunized with a mixture of 
5 mg Ascaris suum  extract (ASE) and alum injected subcutaneously in areas drained by 
axillary and inguinal lymph nodes, 2 wk before each experiment.  One day before each 
study, the sheep were injected intradermally with progressive dilutions of ASE, followed 
by intravenous administration of 23 mg of Evans' blue dye. Sensitized  sheep were defined 
as those showing 5 mm bluing at the site injected with ~0.1 ~g ASE. Sheep not immunized 
with ASE were considered to be nonsensitized controls if there was <5 mm bluing at the 
site injected with 100 ug ASE. 
During general anesthesia (with  1% halothane in oxygen and mechanical ventilation, 
which maintained a constant tidal  volume) a flow-directed pulmonary artery catheter was 
introduced via the left external jugular vein. A right thoracotomy was performed and the 
efferent duct of the caudal mediastinal lymph node was cannulated to obtain pulmonary 
lymph. A left thoracotomy was performed to place a flow meter transducer around the 
systemic and pulmonary arteries.  Hemodynamics, and the flow rate and protein concen- 
trations of lung lymph were monitored for 1-2 h until stable.  Anaphylaxis was induced 
by intravenous administration of 3.0 mg ASE in 5 ml PBS. 
Eicosanoid Assays.  Levels of thromboxane B2 (TXB~) and of the prostacyclin metabo- 
lite,  6-keto-PGF~ were determined by RIA as described previously (7, 8), using antisera 
provided by Dr. L. Levine. Blood was collected in tubes containing 38 mg sodium EDTA 
and  100 ~g indomethacin, and lymph was collected in tubes containing 140 IU heparin; 
0.1-0.2 ml portions of plasma and lymph were assayed for eicosanoids directly, or after 
dilution, as needed. LTs were assayed in lymph and plasma using a slightly modified RIA 
described previously (9). The antiserum to SPLT reacts with LTC4, LTD4, aind LTE4. 
Because significant SPLT activity was found only in sheep lymph and was shown by HPLC 
to consist almost entirely of LTE4, the RIA for SPLT was done primarily to detect LTE4. 
The concentrations of LTE4 were calculated by comparison to standard curves based on 
the  displacement  of [~H]LTC4  by  LTE4.  In  this  assay,  50%  inhibition  of binding of 
[~H]LTC4 occurred at LTE4 concentrations of 1.5 ng in a final volume of 1.0 ml per assay 
tube. In a similar  assay for LTB4, the binding of [SH]LTB4 was inhibited 50% by 0.7 ng 
LTB4 in an assay volume of 1.0 ml. All samples and standards were stored at -80 °. 
Reverse-phase HPLC (RP-HPLC).  A  Waters Associates  (Milford,  MA) system  for RP- 
HPLC, consisting of an  M6000  pump, a  model 440 absorbance detector and a  C18u- 
Bondapak column was  used.  The  LTs were extracted  from  lymph onto Sep-pak  C18 
cartridges (Waters Associates) previously rinsed with methanol and water. After applying 
the lymph, the columns were rinsed with water and hexane, and LTs were eluted with 
methanol. The methanol was removed in a stream of N2, and the residue was reconstituted 
in the HPLC mobile phase. The LT samples  were applied and eluted isocratically  with a 
solvent consisting of 67% methanol, 33% water, and 0.08% glacial acetic acid, neutralized 
to apparent pH  5.5  with 58% aqueous ammonia.  Fractions of 1 ml were collected at a 
flow rate of 1 ml/min. The fractions were prepared for RIA by removing the solvent in 
vacuo using a Speed Vac concentrator (Savant,  Hicksville,  NY) and dissolving the residue 
in Isogel-Tris buffer, pH 7.4. 
Statistical Methods.  Data were analyzed by two-way analysis  of variance with  groups 
and time as factors. 
Materials.  [3H]TXB2,  [SH]6-keto-PGFl~,  and  [SH]LTC4,  were  obtained  from  New 
England Nuclear,  Boston, MA.  Standards of LTC4, LTD4, and  LTE4 were generously 
provided by Dr. J. Rokash, Merck-Frosst, Montreal, Canada. Standard TXB~ and 6-keto- 
PGF~ were purchased from the Upjohn Co., Kalamazoo, MI. Solvents for HPLC were 
of spectral grade (Burdich and Jackson, Muskegon, MI). 
Results 
Cyclooxygenase  Products.  After  monitoring  and  sampling  devices  were  in- 
stalled, baseline measurements were made at 30 or 60 min before challenge with 
ASE.  Indomethacin,  10 mg/kg, was given intravenously to one group of sheep ROBINSON  ET  AL  1511 
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FIGURE  1.  Levels of two  cyclooxygenase products in sheep arterial plasma from antigen- 
challenged sensitized sheep, nonsensitized sheep, and sensitized sheep pretreated with indo- 
methacin. Blood samples were obtained from a catheter in the ascending aorta, and TXB~ and 
6K-PGF]  concentrations were determined by RIA of plasma.  A  sample was obtained from 
each animal either 30  or  60  min before antigenic challenge at t  =  0,  and at several time 
intervals after challenge. Means _-!- SEM are shown. 
60  min before challenge. After ASE challenge of sensitized sheep, there was a 
rapid increase in arterial plasma levels of TXB2 and 6-keto-PGFl~ (Fig.  1); these 
values  returned  to  baseline  levels  within  30  min.  In  some  animals (data  not 
shown), selected measurements were made for an additional 3.5 h after challenge; 
no significant changes from baseline were observed. Statistical analyses showed 
significant differences in TXB2 levels of sensitized (n =  7) compared with both 
nonsensitized (n =  4) and indomethacin-treated (n =  4) groups, p =  0.0001.  For 
6-keto-PGFl,, the sensitized group (n =  7) also differed from both nonsensitized 
(n =  3; p  =  0.007) and indomethacin-treated (n =  3, p  =  0.004)  groups.  Both 
TXB2  and  6-keto-PGFl~  were  measured  in  venous  plasma  and  in  pulmonary 
lymph from two to three sheep in each group (data not shown); in each case, the 
findings paralleled the results shown for arterial plasma. 
LT in Pulmonary Lymph.  Levels of SPLT became markedly elevated in pul- 
monary lymph within 20 min after induction of anaphylaxis in sensitized sheep 1512  CYCLOOXYGENASE  BLOCKADE  RAISES  LEUKOTRIENE  E4  PRODUCTION 
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FIGURE 2.  LTE4  levels  in lung  lymph  from  antigen-challenged  sensitized  sheep, nonsensitized 
sheep, and sensitized  sheep pretreated with indomethacin.  Lymph  was collected from a canu]a 
placed into the efferent duct of the caudal mediastinal lymph node. Samples were collected 
30 or 60 rain before and at several times  after antigenic  challenge at t = 0. 
that  had  been  pretreated  with  indomethacin (Fig.  2).  The  levels  reached  a 
maximum between 40 and 60 min, and gradually declined over the 4-h period 
of observation.  Levels of SPLT did  not become  elevated above prechailenge 
levels in the other two groups of sheep. The concentrations of SPLT are reported 
as LTE4 equivalents based on the results of RP-HPLC analyses described below. 
We also analyzed arterial and venous plasma for SPLT and LTB4 and lymph for 
LTB4 over the time course of these experiments in two or three sheep from each 
of the three groups. Low or undetectable levels of these compounds were found, 
and there was no increase in these levels after antigen challenge. 
It is uncertain whether LTE4 arises from LTC4 and LTD4 in situ in pulmonary 
tissue and lymphatics, in the canula during collection, or whether it arises at both 
sites. We have found that both LTC4 and LTD4 are largely (>80%) converted 
to LTE4 in pulmonary lymph incubated in vitro for 60 min at 37  °C. However, 
in  one experiment, lymph was  collected from an  indomethacin-treated sheep 
during anaphylaxis, and immediately diluted in five volumes of ethanol. Analysis 
by  HPLC and  RIA  using the  methods for the  experiments  shown  in  Fig.  3 
showed that >90% of the SPLT was LTE4, and that LTC4 and LTD4 together 
accounted for <10%  of the sum of these three SPLT. These results show that 
formation of LTE4 from its precursor  SPLT  must have occurred before the 
lymph was collected for analyses. It is possible that formation of LTE4 occurs in 
the  lymphatic system or,  to  some extent,  in  the  canula  draining the  lymph. 
Regardless of the site(s)  of formation of LTE4, there is a  marked elevation of 
SPLT concentration in lung lymph from indomethacin-treated sheep. 
Characterization of  SPLT in Lymph by RP-HPLC.  To further define the material 
detected in lymph from indomethacin-treated sheep, pooled lymph from each of 
two  animals  that  had  elevated  SPLT  levels  was  extracted  and  fractionated 
separately by RP-HPLC. As shown in Fig.  3, all of the SPLT activity detected 
by  RIA  (>1  ng/ml  LTE4  equivalents)  was  found  in  two  or  three  fractions ROBINSON  ET  AL  1513 
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FIGURE 3.  HPLC of pulmonary lymph from antigen-challenged sensitized sheep pretreated 
with indomethacin.  Lymph was  obtained 20-120  min after challenge, and was pooled from 
each of two sheep;  pooled samples  were processed  separately.  Following chromatographic 
separation, each fraction was tested for SPLT by RIA. SPLT activity was detected primarily 
in fractions corresponding to the elution position of the LTE4 standard;  these fractions also 
contained a peak of absorbance at 280 nm. 
corresponding  to  the position  of the  LTE4  standard.  In  both cases, a  peak of 
absorbance at 280 nm was found in fractions of lymph corresponding to elution 
position of the LTE4 standard. 
The  total  amount  of  LTE4  measured  by  RIA  in  fractions  19-21  in  the 
experiments shown in the upper and lower panels of Fig. 3 was ~ 12 and  18 ng, 
respectively. These values were not corrected for losses during  extraction and 
chromatography.  In  other  experiments,  authentic  LTE4  was  extracted  from 
sheep lymph with yields of 40-60%.  We also estimated the quantities of LTE4 
detected  in  each  experiment  based  on  the  integrated  optical  density  of the 
absorbance peaks at the position of the LTE4 marker in Fig.  3.  We assumed a 
molar  extinction  coefficient for  LTE4  of 4.0  x  104/M.cm  a  value previously 
reported  (10)  for  LTC4.  The  amount  of LTE4  in  the  two  experiments  was 
estimated to be 22  +  5  ng,  uncorrected  for yields. This  value is in reasonable 
agreement with the quantities  measured by RIA in the reconstituted fractions. 
Therefore, the SPLT measured in lymph from indomethacin-pretreated  sheep 
appears  to  be  LTE4  on  the  basis  of  its  RP-HPLC  mobility  and  its  optical 
absorbance properties. 
Discussion 
These  studies  showed  that  acute  anaphylaxis,  in  sheep  pretreated  with  an 
amount  of indomethacin  sufficient to  block the  expected  elevation  of plasma 
cyclooxygenase metabolites by >00%,  was associated with marked elevations in 
SPLT levels in pulmonary lymph. Nearly all of the SPLT measured in lymph by 
RIA  was  shown  to  have  the  mobility of LTE4  on  RP-HPLC.  The  maximum 
levels of LTE4 of 75 ng/ml  in sensitized sheep treated with indomethacin  (Fig. 
2) represents at least a fivefold increase above levels in the other two groups of 1514  CYCLOOXYGENASE  BLOCKADE  RAISES  LEUKOTRIENE  E4  PRODUCTION 
sheep (p =  0.0001, for the comparison between indomethacin-treated sensitized 
sheep and the other two groups). It is unclear why increased levels of SPLT are 
found in  lymph while  no  corresponding increases are  found  in  plasma.  It  is 
possible that the larger volume of blood draining the lung may contain lower 
levels of SPLT because of dilution. 
We did not detect LTB4 in lymph in any of our experiments using an RIA of 
nearly 12-fold greater sensitivity for LTB4 than that of the SPLT RIA for LTE4. 
Therefore, levels of LTE4 must have exceeded levels of LTB4 in lymph from 
indomethacin-treated sheep by at least 12-fold. It seems unlikely that our failure 
to detect LTB4 in lymph is related to rapid degradation of this compound in the 
lung. First, we have shown that both LTB4 and LTE4 resist degradation in sheep 
lymph and heparinized blood  in  vitro at  37°C  for  1 h  (D.  Robinson,  and C. 
Melvin, unpublished experiments). Second, others (11) have reported that LTB4 
was not metabolized by isolated perfused rat lung administered either intravas- 
cularly or by inhalation.  We therefore tentatively conclude that more SPLTs 
than LTB4 are produced in sheep lung during anaphylaxis. 
The  production  of greater  quantities  of SPLT  than  LTB4  provides  some 
evidence for the type of cells responsible for LT production in our experiments, 
because the patterns of 5-1ipoxygenase products elaborated by certain cells is 
characteristic. Ionophore-stimulated neutrophils, monocytes, and alveolar mac- 
rophages produce more LTB4 than SPLT,  whereas eosinophils and mast cells 
produce substantially larger (6-35-fold) quantities of SPLT than LTB4 (3). The 
conclusion that greater quantities of SPLT than LTB4 were produced in indo- 
methacin-treated sheep during anaphylaxis is consistent with the mast cell being 
the source of the LTs produced under these conditions. 
The functional changes observed during anaphylaxis in the sheep are complex 
and will be reported elsewhere. In brief, pretreatment of sensitized sheep with 
indomethacin altered their physiologic responses to antigenic challenge in com- 
parison  to those of sensitized sheep.  Indomethacin-treated sheep had reduced 
pulmonary vasoconstriction,  increased cardiac output  in  the first  5  min after 
challenge, and an  impressive degree of late tachycardia (5-30  min after chal- 
lenge), associated with a reduced cardiac output (data not shown). 
The SPLTs are potentially important mediators of anaphylactic hypersensitiv- 
ity reactions. Each of these compounds, LTC4,  LTD4, and LTE4 is biologically 
active (3, 4,  12-15). The SPLTs are potent bronchoconstrictors for both periph- 
eral and central airways (4, 15). Both LTC4 and LTD4 stimulate mucous secretion 
by the bronchial mucosa (16,  17).  The SPLTs increase permeability in several 
vascular beds (3-5). They are potent vasoconstrictors and may markedly reduce 
cardiac output, probably related to both peripheral and coronary artery constric- 
tion (5,  18,  19).  Cyclooxygenase inhibition may modify the response of pulmo- 
nary and vascular tissues to LTs under certain conditions. For example, the in 
vitro LTD4-induced contractile response of sheep trachea, but not of bronchi or 
lung parenchymal strips,  was enhanced by meclofenamate (20).  On the other 
hand,  the increased pulmonary vascular resistance resulting from injection of 
LTD4  into sheep pulmonary artery was inhibited by cyclooxygenase blockade 
(21). 
Several previous studies showed that  cyclooxygenase inhibition  by  NSAIDs ROBINSON ET AL  1515 
may enhance formation of lipoxygenase products in vitro. Indomethacin inhibi- 
tion of TXB2 and HHT synthesis by platelets was associated with increased levels 
of the 12-1ipoxygenase product 12-hydroxyeicosatetraenoic  acid (12-HETE). The 
increased synthesis of 12-HETE was equal to the sum of the reduced synthesis 
of TXB~ and HHT, suggesting that available free arachidonic acid was shunted 
to lipoxygenase products (22). Other in vitro studies showed that cyclooxygenase 
inhibition  augmented  SPLT  activity  in  guinea  pig  trachea  (23)  and  human 
bronchus (24), and also augmented 15-1ipoxygenase products in human neutro- 
phils (25).  More recently, Ham et al.  (26) have shown that PGE~ and PGE2 in 
the range of 10 -7 M inhibited the formation of LTB4 and 5-HETE in cytochalasin 
B-treated rat  neutrophils stimulated by a  chemoattractant peptide.  These au- 
thors suggested that cyclooxygenase inhibitors may augment the synthesis of 5- 
lipoxygenase products by removing the inhibition of this pathway by prostaglan- 
dins (26). In one in vivo study, cyciooxygenase blockade also was associated with 
slight (~40%) elevation in LTB4 synthesis by peritoneal exudates in rats (27). 
The demonstration in our experiments that cyclooxygenase blockade is asso- 
ciated with increased levels of SPLT in vivo suggests that increased production 
of lipoxygenase products  may account for some of the pharmacologic effects 
attributed  to  NSAIDs.  The  results  support  the  hypothesis  that  the  adverse 
pulmonary and circulatory reactions to  NSAIDs in some patients with aspirin 
sensitivity may be related to inhibition of cyclooxygenase and enhanced produc- 
tion of SPLTs (28).  The vasoconstrictor effects of SPLT in renal, cardiac, and 
other vascular beds, (29, 30) raise the possibility that increased SPLT production 
in these organs might contribute to the decreased renal blood  flow, impaired 
renal  function, and aggravation of congestive heart failure observed in  some 
patients treated with NSAIDs. Finally, because the LTs are potent mediators of 
inflammation, the increased production of these compounds during treatment 
with NSAIDs may reduce the therapeutic efficacy of these drugs. 
Summary 
We examined changes in  the levels of eicosanoids in  blood and pulmonary 
lymph of anesthetized sheep undergoing acute anaphylaxis. Within  1-3 min of 
intravenous antigenic challenge of previously sensitized sheep, there were ~7- 
30-fold elevations in mean arterial plasma levels of thromboxane B2 and 6-keto- 
prostaglandin F~, respectively, as measured by RIA. Negligible changes in levels 
of these cyclooxygenase products were found in both nonsensitized sheep and in 
sensitized sheep treated with indomethacin before antigenic challenge. In con- 
trast, no changes in levels of sulfidopeptide leukotrienes (SPLT) in pulmonary 
lymph were detectable by RIA during anaphylaxis in sensitized or nonsensitized 
sheep,  but  levels of SPLT  in  indomethacin-treated sensitized sheep increased 
more than  fivefold above levels in  lymph from both other groups of animals. 
The  immunoreactive SPLT  in  lymph  from  indomethacin-treated sheep  was 
accounted for as LTE4, as demonstrated by mobility on HPLC and absorbance 
at 280 nm. These results support the possibility that certain undesirable effects 
of nonsteroidal antiinflammatory drugs,  such as cardiopulmonary reactions in 
aspirin-sensitive  individuals,  and  impaired  renal  and  cardiac  function during 
therapy with these drugs, may be related in part to augmented synthesis of the 1516  CYCLOOXYGENASE  BLOCKADE  RAISES LEUKOTRIENE E4  PRODUCTION 
5-1ipoxygenase  pathway  products,  especially  those  of the  sulfidopeptide  class. 
Increased LT production  could also limit the antiinflammatory effectiveness of 
these drugs in many disease states. 
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